Cure8 research brief
The review identifies a novel molecular mechanism (S-palmitoylation) that may drive barrier dysfunction and intestinal inflammation in IBD, suggesting new non-immunosuppressive therapeutic targets that could eventually lead to mucosal-healing treatments.
Researchers studying IBD pathogenesis or drug discovery, translational clinicians interested in mucosal-healing approaches, and basic scientists working on protein palmitoylation or innate immune signaling.
This is a review article proposing that protein S-palmitoylation—a reversible lipid modification—regulates intestinal mucosal barrier components (tight junction proteins, MUC2, and receptors like TLR4/NOD2/NLRP3) and innate immune cell phenotypes, with preclinical studies suggesting inhibition of palmitoylation enzymes (e.g., ZDHHCs, APTs/PPTs) or metabolic upstream targets (FASN) can restore barrier function in models of intestinal inflammation.
The review highlights several experimental inhibitors used in preclinical work (broad 2-BP and more selective agents such as ML348 and Palmostatin B) and emphasizes that evidence so far is mainly from in vitro and animal studies.
The authors frame palmitoylation-targeting as a potential pathway for mucosal-healing therapies distinct from classic immunosuppression. This summary is grounded in the article abstract provided and does not represent a full critical appraisal of the entire review or the primary studies cited.
The therapeutic strategies discussed are supported mainly by laboratory and animal-model data; clinical efficacy and safety in people with IBD have not been established. The content here is based on the article abstract (structured content depth: abstract).
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This paper identifies a herbal formula that improved inflammation and epithelial barrier repair in a mouse colitis model and highlights specific molecular pathways (CAV1/FAK/paxillin and metabolite pathways) that might...
The study points to specific immune pathways (especially Th17 differentiation) and molecular targets that might explain DSP’s anti-inflammatory effects in ulcerative colitis, which could guide further preclinical and...
The study identifies a previously unrecognized protein (TNFAIP1) that appears to promote inflammation in ulcerative colitis and proposes a compound (Salidroside) that directly binds and inhibits it in lab and mouse...
